ID: ALA2177904

Max Phase: Preclinical

Molecular Formula: C23H16FN5

Molecular Weight: 381.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC1=N[C@](c2ccncc2)(c2cccc(-c3cncnc3)c2)c2cccc(F)c21

Standard InChI:  InChI=1S/C23H16FN5/c24-20-6-2-5-19-21(20)22(25)29-23(19,17-7-9-26-10-8-17)18-4-1-3-15(11-18)16-12-27-14-28-13-16/h1-14H,(H2,25,29)/t23-/m1/s1

Standard InChI Key:  JTYGZAPMRYLRCN-HSZRJFAPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 381.41

Molecular Weight (Monoisotopic): 381.1390

AlogP: 3.69

#Rotatable Bonds: 3

Polar Surface Area: 77.05

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.31

CX LogP: 2.95

CX LogD: 2.95

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.59

Np Likeness Score: -0.61

References

1. Swahn BM, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J, Berg S, Lindström J, Sundström M, Turek D, Kihlström J, Slivo C, Andersson L, Pyring D, Rotticci D, Ohberg L, Kers A, Bogar K, von Kieseritzky F, Bergh M, Olsson LL, Janson J, Eketjäll S, Georgievska B, Jeppsson F, Fälting J..  (2012)  Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.,  55  (21): [PMID:22924815] [10.1021/jm3009025]

2. Lindgren A, Eklund G, Turek D, Malmquist J, Swahn BM, Holenz J, von Berg S, Karlström S, Bueters T..  (2013)  Biotransformation of two β-secretase inhibitors including ring opening and contraction of a pyrimidine ring.,  41  (5): [PMID:23474650] [10.1124/dmd.112.050351]

Source

Source(1):

• Scientific Literature